Higher doses of heart failure guideline-directed medical therapy prescribed to patients with acute heart failure admission are associated with better outcomes

1. Higher doses of guideline-medical therapy (GDMT) within 2 weeks after discharge from an acute heart failure (AHF) admission were associated with a reduction in 180-day heart failure (HF) readmission, all-cause death, and quality of life (QOL) at 90 days. 2. Patients in high-intensity care (HIC) with higher GDMT doses at week 2 also had

Related Keywords

,Rating Level ,Rapid Optimization ,N Terminal Pro ,Brain Natriuretic Peptide ,Heart Failure Therapies ,Race ,Adhf ,Arb ,Narni ,Gdmt ,Heart Failure ,Umra ,Sglt2i ,Strong Hf ,Cardiology ,